Indaptus Therapeutics (NASDAQ:INDP) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw unusually-high trading volume on Thursday . Approximately 25,631,092 shares traded hands during mid-day trading, an increase of 10,529% from the previous session’s volume of 241,142 shares.The stock last traded at $4.8910 and had previously closed at $2.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Indaptus Therapeutics Stock Performance

The stock has a 50-day moving average price of $2.07 and a two-hundred day moving average price of $2.18. The stock has a market capitalization of $528.15 million, a PE ratio of -0.32 and a beta of 1.25.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($1.87) by $1.64.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is owned by institutional investors and hedge funds.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.